ILIKOS Consulting Group, a Cyprus-based company that offers services to Contract Research Organisations (CROs) and life science companies, announced on Tuesday that it has partnered with Jordan Center for Pharmaceutical Research (JCPR), a pharmaceutical research facility in Jordan.
The partnership is aimed at highlighting the advantages in designing and executing BE/BA studies in Jordan and advancing innovative clinical research across the country.
Elias Sayias, ILIKOS founder and CEO, said: "With increasing global pressures on the generics industry, from regulatory shifts to rising development costs, it's critical to explore innovative and reliable solutions. Jordan's strategic position, combined with JCPR's extensive expertise, offer a compelling value proposition for sponsors navigating the challenges of modern drug development. Our goal is to support bridging cultural, regulatory and operational gaps to deliver cost-effective, high-quality outcomes."
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment